Skip to main content
. 2015 Oct 13;3(4):339–343. doi: 10.1093/gastro/gov051

Figure 2.

Figure 2.

Overall survival curves of group A and group B patients. Overall survival was identical for patients who received bevacizumab (group A) first or cetuximab first (group B) (44.0 vs 39.0 months, P = 0.862).